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Abstract
Background: The incidence of thyroid cancer and the number of patients who die from this disease are increasing
globally. Differentiated thyroid cancer (DTC) is the histologic subtype present in most patients and is primarily
responsible for the increased overall incidence of thyroid cancer. Sorafenib is a multikinase inhibitor that targets
several molecular signals believed to be involved in the pathogenesis of thyroid cancer, including those implicated
in DTC. In phase II studies of patients with DTC, sorafenib treatment has yielded a median progression-free survival
(PFS) of 58 to 84 weeks and disease control rates of 59% to 100%. The DECISION trial was designed to assess the
ability of sorafenib to improve PFS in patients with locally advanced or metastatic, radioactive iodine (RAI)-
refractory DTC.
Methods/design: DECISION is a multicenter, double-blind, randomized, placebo-controlled phase III study in
patients with locally advanced/metastatic RAI-refractory DTC. Study treatment will continue until radiographically
documented disease progression, unacceptable toxicity, noncompliance, or withdrawal of consent. Efficacy will be
evaluated every 56 days (2 cycles), whereas safety will be evaluated every 28 days (1 cycle) for the first 8 months
and every 56 days thereafter. Following disease progression, patients may continue or start sorafenib, depending
on whether they were randomized to receive sorafenib or placebo, at investigator discretion. Patients originally
randomized to receive sorafenib will be followed up every 3 months for overall survival (OS); patients originally
randomized to receive placebo will be followed up every month for 8 months after cross-over to sorafenib. The
duration of the trial is expected to be 30 months from the time the first patient is randomized until the planned
number of PFS events is attained. The primary endpoint is PFS; secondary endpoints include OS, time to disease
progression, disease control rate, response rate, duration of response, safety, and pharmacokinetic analysis.
Discussion: The DECISION study has been designed to test whether sorafenib improves PFS in patients with
locally advanced or metastatic RAI-refractory DTC.
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Background
In the United States in 2010, there were 44,670 esti-
mated new cases of thyroid cancer, making it the most
common of the endocrine malignancies [1]. The inci-
dence of thyroid cancer is increasing globally, as is the
number of patients who die from this disease [2,3]. Dif-
ferentiated thyroid cancer (DTC) is the histologic sub-
type present in most patients, as well as being primarily
responsible for the increased overall incidence of thyroid
cancer [4].
Therapeutic options for patients with radioiodine
(RAI)-refractory, advanced DTC are limited. The only
systemic therapy approved in most countries is doxoru-
bicin, which has traditionally been a limited option
because complete responses are rare, partial responses
are limited, and toxicity is considerable [5]. DTC is
therefore a disease in which new therapeutic options
with favorable toxicity profiles are greatly needed.
Sorafenib is a multikinase inhibitor that targets several
molecular signals believed to be involved in the patho-
genesis of thyroid cancer, including those implicated in
DTC. These signals include the RAS and BRAF/MEK/
ERK signaling pathways; ligand-independent RET/PTC
receptor tyrosine kinase activation; and pathways invol-
ving vascular endothelial growth factor (VEGF), platelet-
derived growth factor (PDGF), and their receptors (Fig-
ure 1).
A total of 168 patients with thyroid cancer, including
133 (79%) with differentiated histology, have been
treated with sorafenib in four phase II trials (Table 1).
Median progression-free survival (PFS) ranged from 58
weeks to 84 weeks, partial responses (PRs) were
observed in up to 25% of patients, and disease control
rate (DCR [stable disease + partial response]) ranged
from 59% to 100%. These results were achieved despite
dose reductions due to adverse events (AEs) in up to
62% of patients. Most AEs experienced by patients in
these phase II trials were grade 1 or 2 and were
manageable.
Rationale for phase III study
Given the encouraging results from phase II trials of
sorafenib in patients with DTC and the need for
improvement in the treatment of thyroid cancer, the
phase III DECISION (Study of Sorafenib in Locally
Advanced or Metastatic Patients with RAI-Refractory
Thyroid Cancer) trial was initiated to evaluate the effi-
cacy and safety of sorafenib in patients with locally
advanced or metastatic, RAI-refractory, DTC. Because
PFS may better predict improvement in overall survival
(OS) than response rate, PFS was selected as the pri-
mary efficacy assessment.
Methods/design
Primary Objective
Patients with RAI-refractory DTC (papillary, follicular,
Hürthle cell, and poorly differentiated carcinoma) are
being randomized to receive sorafenib or placebo. The
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Figure 1 Molecular signals believed to be involved in the pathogenesis of DTC. Key events in the initiation of thyroid cancer are believed
to include constitutive activation of BRAF, RAS, and RET/PTC [17,18].
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PFS, as evaluated by Response Evaluation Criteria in
Solid Tumors version 1.0 (RECIST)[6], in the sorafenib
and placebo groups. PFS is defined as the time from
date of randomization to the date of radiologic progres-
sion or death (if death occurs before progression).
Secondary Objectives
Among the secondary efficacy objectives of this trial are
OS, measured from date of randomization to date of
death due to any cause; time to progression (TTP), mea-
sured from date of randomization to date of confirmed
radiologic progression; and disease control rate (DCR),
defined as the proportion of patients with a best overall
tumor response of complete response (CR), PR, or stable
disease (SD) based on RECIST criteria, during treatment
or within 30 days of termination of study medication.
Other secondary efficacy objectives include response
rate (RR), defined as the proportion of patients with a
best overall tumor response of PR or CR during treat-
ment or within 30 days of termination of study medica-
tion; and duration of response (DoR), defined as the
time from first documented objective response of PR or
CR (whichever is noted earlier) to disease progression or
death (if death occurs before progression is documen-
ted). Secondary safety objectives include assessment of
AEs and abnormalities in laboratory parameters. Phar-
macokinetic (PK) objectives include determinations of
exposure to sorafenib, defined as the area under the
concentration (AUC) time curve from time 0 to 12
hours (AUC0-12) by population PK methods and using
previously developed sorafenib population PK models.
Design/Randomization
DECISION is a randomized, double-blind, placebo-con-
trolled, phase III trial, in which approximately 380
patients will be randomized 1:1 to receive sorafenib or
placebo (Figure 2).
Stratification
Patients are being stratified at randomization according
to age (< 60 vs ≥ 60 years) and geographic region
(North America vs Europe vs Asia).
Setting
The study setting is multinational, with approximately
91 sites in North America, Europe, and Asia. Patients
are currently being enrolled in 19 countries: the United
Table 1 Phase II trials of sorafenib in DTC
Trial Efficacy Results Grade ≥ 3 AEs in ≥ 5%
of Patients
Other
Single-arm trial
(N = 55 total;
n = 47 DTC) [10-12]
mPFS = 84
weeks*
SD = 53.3%
†
PR = 23.3%
†
DCR = 76.6%
†
OS = 140
weeks
†
Hypertension (13%), hand-foot syndrome
(10%), rash (10%), weight loss (10%), diarrhea
(7%), elevated LFTs (7%)
‡
￿ Dose reduction (due to AEs) was required
in 47% of patients (initial analysis)
￿ Median duration of treatment at initial
analysis (30 of 55 patients accrued) = 27
weeks
￿ BRAF genotyping (n = 16): mPFS = 84+
weeks in DTC patients with BRAF
V600E,
compared with 54 weeks in those with
BRAF
wt (P = 0.028)
Single-arm component
(chemotherapy-naive patients with
DTC) of two-arm trial (N = 56 total;
n = 41 DTC) [13]
mPFS = 65
weeks*
SD = 57%*
PR = 15%*
DCR = 72%*
Fatigue, HSFR (11% each); weight loss, skin
rash, hypertension, diarrhea, stomatitis,
tongue/tooth pain, abdominal/rectal pain,
proximal myopathy, back pain, general pain,
hand/foot pain, arthralgia, colon perforation
(5% each)
￿ Dose reduction (due to AEs) was required
in 52% of patients
Single-arm trial
(N = 26 total;
n = 14 DTC) [14,15]
mPFS not
reported
SD = 82%
†
PR = 18%
†
DCR = 100%
†
Hand-foot syndrome (19%), other skin toxicity
(6%),
hypertension (6%), infection (8%)
￿ Dose reduction (due to AEs) was required
in 62% of patients
￿ Five drug-related serious AEs were
reported:
2 hospitalizations for non-neutropenic fever/
infection, 1 for hypocalcemia, and 2 for
fever/rash
Single-arm trial
(N = 31; all DTC) [16]
mPFS = 58
weeks
SD = 34%
PR = 25%
DCR = 59%
HFSR (22%), hypertension (16%), weight loss
(9%)
￿ Dose reduction (due to AEs) was required
in 56% of patients
*DTC cohort
†Total study sample
‡One patient developed grade 3/4 LFT abnormalities at 8 weeks and died of liver failure 12 weeks later
DTC = differentiated thyroid cancer; mPFS = median progression-free survival; SD = stable disease; PR = partial response;
DCR = disease control rate; LFTs = liver function tests; HFSR = hand-foot skin reaction; AE = adverse event
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Spain, Sweden, Netherlands, Austria, Belgium, China,
South Korea, Japan, Russia, Slovakia, Bulgaria, and Saudi
Arabia.
Ethics, Informed Consent, and Safety
Documented approval has been obtained from appropriate
Ethics Committees/Institutional Review Boards at all parti-
cipating centers/countries prior to study start. The study is
also designed to conform to International Conference on
Harmonization of good clinical practice (GCP) guidelines,
local laws, regulations, and organizations, as well as with
the Declaration of Helsinki. Written informed consent
must be obtained from each patient before any study-spe-
cific procedure takes place. Participation in the study and
date of informed consent patient are being documented
appropriately in each patient’s files. A Data Monitoring
Committee is in place to monitor the trial.
Eligibility
Inclusion Criteria
All patients must be > 18 years of age, have a life expec-
tancy of at least 12 weeks, and have locally advanced or
metastatic DTC (papillary, follicular, Hürthle cell, or
poorly differentiated carcinoma) with at least one mea-
surable lesion as measured by computed tomography
(CT) or magnetic resonance imaging (MRI) and disease
progression within 14 months. Patients must not be
candidates for curative surgery or radiation therapy.
Additional inclusion criteria are an Eastern Cooperative
Oncology Group (ECOG) performance status ≤ 2[ 7 ] ;
adequate thyroid-stimulating hormone (TSH) suppres-
sion (< 0.5 mU/L); and adequate bone marrow, liver,
and renal function. All patients must have RAI-refrac-
tory disease, defined as a target lesion with no iodine
uptake on a post-RAI scan performed under conditions
of a low iodine diet and adequate TSH elevation or
recombinant human TSH (rhTSH) stimulation. How-
ever, certain patients who have had some iodine uptake
may also be eligible. They include: (1) patients who have
undergone a single RAI treatment (≥ 3.7 GBq [≥ 100
mCi]) within the previous 16 months, and who have
progression of the target lesion despite RAI treatment;
(2) patients who have had multiple RAI treatments, with
the last RAI treatment > 16 months ago, and who had
disease progression after each of two RAI treatments (≥
3.7 GBq [≥ 100 mCi] each) administered within 16
months of each other; and (3) those who have received
a cumulative RAI dose of ≥ 22.2 GBq (≥ 600 mCi).
Exclusion Criteria
Patients who undergo major surgery, open biopsy, or
significant traumatic injury ≤ 30 days prior to randomi-
zation; those with previous or concurrent cancer dis-
tinct in primary site or histology from thyroid cancer ≤
5 years prior to randomization, except for cervical can-
cer in situ, treated basal-cell carcinoma, and superficial
(Ta, Tis, or T1) bladder tumors; and patients with foci
of undifferentiated thyroid cancer are being excluded
from the study. Other exclusion criteria include the pre-
sence of a non-healing wound, ulcer, bone fracture, or
grade ≥ 2 infection according to National Cancer Insti-
tute Common Terminology Criteria for Adverse Events
(NCI-CTCAE) v3.0 [8], a grade ≥ 3 hemorrhage or
bleeding event according to NCI-CTCAE ≤ 3m o n t h s
prior to randomization; evidence or history of bleeding
diathesis or coagulopathy; or the presence of tracheal,
bronchial, or esophageal infiltration with significant risk
of bleeding (but without having received local treatment
prior to enrollment in the study). Patients with clinically
significant cardiac disease and/or uncontrolled hyper-
tension (> 150/90 mm Hg) despite optimal treatment;
those known to be infected with human immunodefi-
ciency virus (HIV) or hepatitis B (HBV) or C (HCV)
virus; women who are pregnant or breastfeeding; and
patients with a known or suspected allergy to sorafenib
or hypersensitivity to sorafenib or any agent given dur-
ing the course of the study are also being excluded.
Excluded Therapies and Medications
Patients are being excluded if they had been treated
for cancer with any licensed or investigational
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Figure 2 DECISION schema.
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Page 4 of 7tyrosine kinase inhibitors; monoclonal antibodies that
target vascular endothelial growth factor (VEGF),
VEGF receptors, or other targeted agents; cytotoxic
chemotherapy agents (except for prior low-dose che-
motherapy for radiosensitization); or thalidomide or
any of its derivatives. Enrolled patients are unable to
receive concomitant RAI, chemotherapy, or other
investigational therapy; or any substances known
to induce CYP3A4 (eg, St. John’s Wort, dexametha-
sone > 16 mg daily, phenytoin, carbamazepine, rifam-
pin, rifabutin, phenobarbital) within 7 days of
randomization.
Concomitant Medication Precautions
Patients taking medications with a narrow therapeutic
index (eg, warfarin) are being proactively monitored. In
addition, because sorafenib inhibits a variety of liver
metabolic enzymes in vitro, patients taking concomitant
medications known to be metabolized by the liver are
being monitored closely for AEs associated with those
medications, especially as the clinical effects of sorafenib
in patients taking drugs metabolized by these enzymes
are unknown.
Estimated Timeline
The expected study duration is 30 months. The study
will be halted when data for the primary endpoint are
mature. Any patients continuing to benefit from treat-
ment at the time of the study endpoint will be allowed
to continue treatment.
Treatments
Patients are being randomized to receive sorafenib 400
mg or matching placebo (2 tablets), twice daily (approxi-
mately every 12 hours apart without food; at least 1
hour before or 2 hours after a meal) in a double-blind
fashion; neither the investigator nor the patient (or
sponsor) will know which agent is being administered.
Treatment will be continued until radiographically
documented disease progression, unacceptable toxicity,
or the study endpoint. Sorafenib will be made available,
via an extension program or other mechanism, to
patients who continue to show benefit after the study
endpoint, until disease progression or unacceptable
toxicity.
In the event of confirmed radiologic progression, as
determined by RECIST v1.0 criteria, study treatment
may be unblinded. Patients who had been randomized
to receive sorafenib may continue to receive sorafenib,
whereas those randomized to receive placebo may cross
over to sorafenib. Decisions about continuing study
medication and cross-over will be made by the investi-
gator, based on each patient’s clinical status and the
determination of the investigator that the patient may
receive clinical benefit from sorafenib.
Safety Assessments
Patients are being assessed for safety every 28 days (1
cycle) for the first 8 months and every 56 days (2 cycles)
thereafter (Figure 3). Patients are being monitored for
AEs using NCI-CTCAE v3.0 criteria. Treatment-emer-
gent AEs and safety laboratory parameters will be sum-
marized by treatment group.
Efficacy Assessments
Efficacy is being evaluated every 56 days. Following pro-
gressive disease and at the discretion of the investigator,
patients may continue or start sorafenib, depending on
the treatment arm. Patients treated after progressive dis-
ease will be followed for efficacy until further progres-
sive disease and for safety until 30 days after the end of
sorafenib treatment. Dose modifications or interruptions
are being allowed, based on specific criteria, for grade 2-
3 hand-foot skin reaction (HFSR) and other AEs.
Patients will enter the long-term follow-up period upon
discontinuation of randomized therapy (sorafenib or pla-
cebo), based on documentation of progressive disease or
unacceptable toxicity.
Statistical Analysis
The primary population for efficacy analysis will be the
intention-to-treat (ITT) population, defined as all rando-
mized patients. The population for safety analysis will
consist of all patients who receive at least one dose of
study medication. All randomized patients (ITT
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Figure 3 Safety assessments (A) Patients treated with sorafenib
during the double-blind treatment period and those treated with
sorafenib who experience PD before completing 8 cycles and are
unblinded (open-label treatment period). (B) Patients who received
placebo during the double-blind treatment period and then crossed
over to sorafenib after unblinding.
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Page 5 of 7population) will be included in the primary analysis. The
primary efficacy endpoint is PFS, with analysis per-
formed when a predetermined number of PFS events
has occurred. The null hypothesis–that both treatment
arms have the same PFS distribution–will be tested
against the alternative hypothesis–that the distribution
of PFS in the two arms will differ according to Leh-
mann’s alternative.
The two treatment groups (sorafenib and placebo) will
be compared using a one-sided stratified log-rank test,
with an overall one-sided alpha of 0.01 stratified by age
(< 60 years vs ≥ 60 years) and geographica region
(North America, Europe, and Asia). Kaplan-Meier esti-
mates of median times to PFS and Kaplan-Meier curves
will be generated for each group. The hazard ratios and
95% confidence intervals will be derived from a Cox
proportional hazards model.
The secondary efficacy endpoints of TTP and OS in
each group will be analyzed by the Kaplan-Meier
method and compared using the log-rank test. Response
rate and DCR will be analyzed using the Cochran-Man-
tel-Haenszel test. The tests will be adjusted for the same
stratification factors as used for PFS. Duration of
response and the exploratory endpoints will be analyzed
with descriptive statistics only.
Discussion
Currently, there is no standard of care for the treatment
of patients with advanced, RAI-refractory DTC [9]. In
designing the randomized, placebo-controlled DECI-
SION study, we hypothesized that the inclusion of a
cross-over component would likely be the best approach
to recruit and retain patients in this study. Although
this design precludes an endpoint such as OS, patients
with advanced DTC may derive benefit from a well-tol-
erated therapy such as sorafenib. Therefore, DECISION
is designed to demonstrate PFS when patients with
locally advanced or metastatic RAI-refractory DTC are
treated with sorafenib.
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